Vaccibody AS - Private Placement - NOK 230 million
The net proceeds will i.a. be used to conduct a Phase IIa clinical study combining Vaccibody’s product candidate VB10.16 with Roche’s checkpoint inhibitor Atezolizumab, prepare for expansion cohorts in Vaccibody’s VB10.NEO cancer neoantigen programme and initiation of two expansion cohorts.
Latest news
Arctic Securities - IMPORTANT NOTICE — ARCTICSAS
Arctic Securities is not affiliated with "Arctic SAS" or www.arcticsas.com.
We have been made aware that unknown parties are using the Arctic Securities name, logo and trademark in connection with investment offers directed at private individuals abroad.
Arctic Securities - Arctic Securities ramps up its Swedish operations
Arctic Securities ramps up its Swedish operations with new key hires in Stockholm to strengthen its full-service Nordic investment bank offerings. Gustav Rosén will assume the role of CEO Sweden.
Arctic Securities - TÝR Markets and Arctic Securities form a collaboration
TÝR Markets and Arctic Securities form a collaboration providing clients access to selected digital assets in a fast-growing market
Arctic Securities - Strong Attendance and Clear Demand Signals at the Arctic Seafood Conference 2025
Arctic Securities welcomed nearly 400 participants to this year’s Arctic Seafood Investor Conference at Hotel Continental, where global demand dynamics took centre stage.
Arctic Securities - Arctic med flere pallplasser og størst vekst på meglerbordet
Arctic Securities tar ni pallplasser i Kapitals årlige meglerhuskåring, med Norges beste aksjemeglere og størst vekst på meglerbordet.
Arctic Securities - Arctic top-ranked in Prospera 2025
Arctic Securities secured several leading positions in the Prospera Nordic High Yield Investor Survey 2025.